Advertisement

Neurologic Catastrophe in the CT ICU: A Neurosurgeon’s Dilemma

  • Emily P. Sieg
  • Russell A. Carter
  • Shelly D. TimmonsEmail author
Chapter
Part of the Difficult Decisions in Surgery: An Evidence-Based Approach book series (DDSURGERY)

Abstract

Neurosurgical emergencies in the Cardiothoracic Surgery Intensive Care Unit (CTICU) are primarily comprised of intracerebral hemorrhages occurring as a result of thromboembolic ischemic infarction with hemorrhage conversion, falls resulting in traumatic hemorrhages and spontaneous hemorrhagic complications, all of which are complicated by the antithrombotic medication (ATM) regimens required for implanted cardiac devices. Ischemic cerebral infarctions requiring decompressive craniotomy may also occur but are not a focus of this chapter, which will instead concentrate on hemorrhagic intracranial complications related to ventricular assist devices and valve surgery in the absence of bacterial endocarditis or mycotic aneurysms. Resumption of antithrombotic medications after intracranial hemorrhage (ICH) in the face of thrombogenic cardiac devices is an oft-encountered clinical dilemma for which little data exist, and will also be discussed.

Keywords

Intracerebral hemorrhage Intraparenchymal hemorrhage Intraventricular hemorrhage Subarachnoid hemorrhage Subdural hematoma Left ventricular assist device Valve replacement Valve surgery Antithrombotic medications Antiplatelet medications Anticoagulant medications Anticoagulation 

References

  1. 1.
    Floyd TF, Cheung AT, Stecker MM. Postoperative neurologic assessment and management of the cardiac surgical patient. Semin Thorac Cardiovasc Surg. 2000;12:337–48.CrossRefGoogle Scholar
  2. 2.
    Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRefGoogle Scholar
  3. 3.
    Cooper LB, DeVore AD, Michael FG. The impact of worsening heart failure in the United States. Heart Fail Clin. 2015;11:603–14.CrossRefGoogle Scholar
  4. 4.
    Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.CrossRefGoogle Scholar
  5. 5.
    Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefGoogle Scholar
  6. 6.
    Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg. 1999;67:723–30.CrossRefGoogle Scholar
  7. 7.
    Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6:517–26.CrossRefGoogle Scholar
  8. 8.
    Saeed O, Jermyn R, Kargoli F, et al. Blood pressure and adverse events during continuous flow left ventricular assist device support. Circ Heart Fail. 2015;8:551–6.CrossRefGoogle Scholar
  9. 9.
    Saeed O, Shah A, Kargoli F, et al. Antiplatelet therapy and adverse hematologic events during heart mate II support. Circ Heart Fail. 2016;9:e002296.CrossRefGoogle Scholar
  10. 10.
    Kulik A, Rubens FD, Baird D, et al. Early postoperative anticoagulation after mechanical valve replacement: a Canadian survey. J Heart Valve Dis. 2006;15:581–7.PubMedGoogle Scholar
  11. 11.
    Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis. 2005;14:576–82.PubMedGoogle Scholar
  12. 12.
    Suri RM, Thourani VH, He X, et al. Variation in warfarin thromboprophylaxis after mitral valve repair: does equipoise exist and is a randomized trial warranted? Ann Thorac Surg. 2013;95:1991–8. discussion 8–9CrossRefGoogle Scholar
  13. 13.
    Schwann TA, Habib RH, Suri RM, et al. Variation in warfarin use at hospital discharge after isolated bioprosthetic mitral valve replacement: an analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Chest. 2016;150:597–605.CrossRefGoogle Scholar
  14. 14.
    Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.CrossRefGoogle Scholar
  15. 15.
    Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev. 2013;7:CD003464.Google Scholar
  16. 16.
    Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in HeartMate II and HeartWare left ventricular assist devices: a systematic review. Neurocrit Care. 2017;27:17–25.CrossRefGoogle Scholar
  17. 17.
    Pae WE, Connell JM, Boehmer JP, et al. Neurologic events with a totally implantable left ventricular assist device: European LionHeart Clinical Utility Baseline Study (CUBS). J Heart Lung Transplant. 2007;26:1–8.CrossRefGoogle Scholar
  18. 18.
    Ramey WL, Basken RL, Walter CM, Khalpey Z, Lemole GM Jr, Dumont TM. Intracranial hemorrhage in patients with durable mechanical circulatory support devices: institutional review and proposed treatment algorithm. World Neurosurg. 2017;108:826–35.CrossRefGoogle Scholar
  19. 19.
    Drews TN, Loebe M, Jurmann MJ, Weng Y, Wendelmuth C, Hetzer R. Outpatients on mechanical circulatory support. Ann Thorac Surg. 2003;75:780–5. discussion 5CrossRefGoogle Scholar
  20. 20.
    Wilson TJ, Stetler WR Jr, Al-Holou WN, Sullivan SE, Fletcher JJ. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118:1063–8.CrossRefGoogle Scholar
  21. 21.
    Steffen RJ, Blackstone EH, Smedira NG, et al. Optimal timing of heart transplant after HeartMate II left ventricular assist device implantation. Ann Thorac Surg. 2017;104:1569–76.CrossRefGoogle Scholar
  22. 22.
    Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefGoogle Scholar
  23. 23.
    Bhat G, Kumar S, Aggarwal A, et al. Experience with noncardiac surgery in destination therapy left ventricular assist devices patients. ASAIO J. 2012;58:396–401.CrossRefGoogle Scholar
  24. 24.
    Wong JK, Chen PC, Falvey J, et al. Anticoagulation reversal atrategies for left ventricular assist device patients presenting with acute intracranial hemorrhage. ASAIO J. 2016;62:552–7.CrossRefGoogle Scholar
  25. 25.
    Jennings DL, Jacob M, Chopra A, Nemerovski CW, Morgan JA, Lanfear DE. Safety of anticoagulation reversal in patients supported with continuous-flow left ventricular assist devices. ASAIO J. 2014;60:381–4.CrossRefGoogle Scholar
  26. 26.
    Piper C, Hering D, Langer C, Horstkotte D. Etiology of stroke after mechanical heart valve replacement – results from a ten-year prospective study. J Heart Valve Dis. 2008;17:413–7.PubMedGoogle Scholar
  27. 27.
    Nishimura K, Koga M, Minematsu K, et al. Intracerebral hemorrhage in patients after heart valve replacement. J Neurol Sci. 2016;363:195–9.CrossRefGoogle Scholar
  28. 28.
    Akhtar RP, Abid AR, Zafar H, Khan JS. Aniticoagulation in patients following prosthetic heart valve replacement. Ann Thorac Cardiovasc Surg. 2009;15:10–7.PubMedGoogle Scholar
  29. 29.
    AlKherayf F, Xu Y, Gandara E, Westwick H, Moldovan ID, Wells PS. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: systematic review and meta-analysis. Thromb Res. 2016;144:152–7.CrossRefGoogle Scholar
  30. 30.
    AlKherayf F, Xu Y, Westwick H, Moldovan ID, Wells PS. Timing of anticoagulant re-initiation following intracerebral hemorrhage in mechanical heart valves: survey of neurosurgeons and thrombosis experts. Clin Neurol Neurosurg. 2017;154:23–7.CrossRefGoogle Scholar
  31. 31.
    Chandra D, Gupta A, Grover V, Kumar Gupta V. When should you restart anticoagulation in patients who suffer an intracranial bleed who also have a prosthetic valve? Interact Cardiovasc Thorac Surg. 2013;16:520–3.CrossRefGoogle Scholar
  32. 32.
    Amin AG, Ng J, Hsu W, et al. Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas. Neurocrit Care. 2013;19:90–4.CrossRefGoogle Scholar
  33. 33.
    Krittalak K, Sawanyawisuth K, Tiamkao S. Safety of withholding anticoagulation in patients with mechanical prosthetic valves and intracranial haemorrhage. Intern Med J. 2011;41:750–4.CrossRefGoogle Scholar
  34. 34.
    Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998;42:769–73.CrossRefGoogle Scholar
  35. 35.
    Gronseth GSCJ, Gloss D, Merillat S, Dittman J, Armstrong MJ, Getchius TS. Clinical practice guideline process manual. Minneapolis: American Academy of Neurology; 2017.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Emily P. Sieg
    • 1
  • Russell A. Carter
    • 2
  • Shelly D. Timmons
    • 1
    Email author
  1. 1.Department of NeurosurgeryPenn State University Milton S. Hershey Medical CenterHersheyUSA
  2. 2.Department of Cardiothoracic SurgeryGeisinger Health SystemDanvilleUSA

Personalised recommendations